Anastasis: A Novel Cell Survival Mechanism
Anastasis: A Novel Cell Survival Mechanism
批准号:
10713750
负责人:
Ho Lam Tang
金额:
$40.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-22 至 2028-08-31
关键词:
AnimalsApoptosisApoptoticBioinformaticsBiosensorBrain InjuriesCASP3 geneCancer cell lineCardiac MyocytesCell DeathCell Death InductionCell Death ProcessCell Differentiation processCell Membrane PermeabilityCell SurvivalCellsCessation of lifeCytoprotectionDrosophila genusEmbryonic DevelopmentEventExhibitsFoundationsGenesGeneticHeart failureHomeostasisHumanIn VitroKnowledgeLabelMammalian CellMolecularMorphologyMusNeuronsOuter Mitochondrial MembranePathologicPhysiologicalPlayPost-Translational Protein ProcessingProteinsProteomicsRattusRecoveryRecurrenceRecurrent diseaseRegulationRoleSystemTestingTherapeuticTissuesXenograft procedurecancer cellcancer survivalcancer therapyclinically relevanteggin vivoinsightmouse modelnovelnovel therapeutic interventionpharmacologicpreservationsmall moleculestable cell linetherapeutic targettool
中文摘要
吻合:一种新的细胞存活机制
英文摘要
Anastasis: A Novel Cell Survival Mechanism
Project Summary
Anastasis is a newly discovered cell recovery mechanism that rescues apoptotic cells from the brink of death.
Challenging the classic view of irreversible apoptosis, we have discovered robust reversibility of apoptosis in
three types of mouse/rat primary cells, twelve human cancer cell lines, and egg chambers in fruit flies. What are
the physiological functions, pathological roles, and therapeutic potentials of anastasis? Anastasis could
be an unexpected cytoprotective mechanism for preserving terminally differentiated cells and tissues that are
difficult to replace, such as cardiomyocytes and neurons. If true, enhancing anastasis may be beneficial for
treating heart failure and brain injury. Besides, anastasis could be an unrecognized escape tactic enabling cancer
cells to survive cancer therapy, thereby contributing to disease recurrence. If confirmed, suppressing anastasis
in dying cancer cells may promote cancer cell death and reduce the chances of recurrence. Anastasis may also
play important roles in limiting apoptosis during embryonic development and normal homeostasis. If identified,
understanding its regulation can provide new insights into the control of cell death and survival in physiological
conditions. However, there are several challenges of testing these hypotheses. It is difficult to track anastasis,
especially in vivo, because cells that have reversed apoptosis are morphologically indistinguishable from healthy
cells. There are no anastasis-specific hallmarks identified, and the regulators of anastasis remain undiscovered.
Here, we will overcome many of these challenges by developing a novel and highly specific tracking system to
label anastatic cells for mammalian studies, and to identify the key regulators of anastasis. To mark anastatic
cells, we will create an anastasis biosensor that can tag anastatic cells with permanent expression of a
fluorescent protein only after they have recovered from both mitochondrial outer membrane permeabilization
(MOMP) and caspase-3 activation, the two most recognized apoptotic events, making this biosensor system
highly specific to anastasis. We will establish anastasis biosensor stable cell lines to determine reversibility of
apoptosis in vitro, and will employ biosensor xenografts to interrogate anastasis in vivo using clinically relevant
mouse models. To elucidate the mechanism of anastasis, we will identify its key regulators, through proteomics,
genetics, and pharmacological approaches. We will identify which genes exhibit up- or down-expression
(potential anastasis regulators, and therapeutic targets) during different stages of anastasis, determine whether
specific post-translational modifications distinguish anastatic cells, establish whether cells that recover from
different cell death inductions share similar molecular features, and investigate how interfering with anastasis
regulator candidates could modulate the reversibility of apoptosis. We will identify small molecules that target
the candidates by bioinformatics, and test their efficacy in promoting or suppressing anastasis in vitro.
Successful completion of this project will generate essential tools and knowledge for studying anastasis, thereby
laying a strong foundation for developing revolutionary new therapeutic approaches by controlling anastasis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidating connections between anastasis and cancer drug resistance
-
批准号:10056879
-
项目类别:
-
资助金额:$41.11万
-
财政年份:2020
-
负责人:Ho Lam Tang
-
依托单位:
Cell survival by anastasis, a novel therapeutic target in cancer
-
批准号:9751798
-
项目类别:
-
资助金额:$16.2万
-
财政年份:2017
-
负责人:Ho Lam Tang
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: